drugset / Trial / NCT00442234
Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To investigate PK and coagulating and fibrinolytic parameter profiles (PD) at the approved dose (13,750 - 27,500 IU/kg) in patients with acute pulmonary embolism accompanying hemodynamic instability.
Timeline
- Start
- 2007-05-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Monteplase | Protein / enzyme biologic | 13750 iu/kg | — |
| Subject | Monteplase | Protein / enzyme biologic | 27500 iu/kg | — |